Inside the New Abbott: A Lot Like the Old Abbott But Without Humira

Last week we profiled AbbVie, the soon to be created spinoff of Abbott (click ticker for report: ). AbbVie will house the firm’s most famous drug, Humira, as well as the rest of the company’s proprietary pharmaceuticals. Essentially, the new Abbott isn’t much different from the old Abbott, minus the blockbuster drug Humira and other members of its drug lineup like AndroGel and TriCor.

The “new” Abbott will have four segments: Established (generic) Pharmaceuticals; Nutritionals; Diagnostics; and Vascular Products. Let’s take a look at the new Abbott’s business and see what’s in store for the new company.

Established Pharmaceuticals

Abbott’s Established Pharmaceuticals business generated $2.9 billion in sales as recently as 2009. However, the company purchased Piramal Healthcare Limited’s generic drugs business, which is one of the largest branded generics businesses in India. The acquisition greatly expanded Abbott’s product lines, and the segment generated $5.4 billion of revenue in 2011.